maxigra max 50 mg tabletki powlekane
zakłady farmaceutyczne polpharma s.a. - sildenafili citras - tabletki powlekane - 50 mg
tadalafil maxigra 10 mg tabletki powlekane
zakłady farmaceutyczne polpharma s.a. - tadalafilum - tabletki powlekane - 10 mg
maxigra go 25 mg tabletki powlekane
zakłady farmaceutyczne polpharma s.a. - sildenafilum - tabletki powlekane - 25 mg
primene 10% - roztwór do infuzji
baxter polska sp. z o.o. - l-izoleucyna + l-leucyna + l-walina + l-lizyna + l-metionina + l-fenyloalanina + l-treonina + l-tryptofan + l-arginina + l-histydyna + l-alanina + kwas l-asparaginowy + l-cysteina + kwas l-glutaminowy + glicyna + l-prolina + l-seryna + l-tyrozyna + l-ornityny chlorowodorek + tauryna - roztwór do infuzji - -
zabak 0,25 mg/ml krople do oczu, roztwór
laboratoires thea - ketotifeni hydrofumaras - krople do oczu, roztwór - 0,25 mg/ml
cabazitaxel accord
accord healthcare s.l.u. - kabazytaksel - nowotwory gruczołu krokowego, odpornego Łożysko - Środki przeciwnowotworowe - treatment of patients with hormone refractory metastatic prostate cancer previously treated with a docetaxel-containing regimen.
kimmtrak
immunocore ireland limited - tebentafusp - uveal neoplasms - Środki przeciwnowotworowe - kimmtrak is indicated as monotherapy for the treatment of human leukocyte antigen (hla)-a*02:01-positive adult patients with unresectable or metastatic uveal melanoma.
cabazitaxel fresenius kabi 20 mg/ml koncentrat do sporządzania roztworu do infuzji
fresenius kabi polska sp. z o.o. - cabazitaxelum - koncentrat do sporządzania roztworu do infuzji - 20 mg/ml
silcontrol 25 mg tabletki powlekane
zentiva, k.s. - sildenafili citras - tabletki powlekane - 25 mg
libtayo
regeneron ireland designated activity company (dac) - cemiplimab - rak, płaskonabłonkowy - Środki przeciwnowotworowe - cutaneous squamous cell carcinomalibtayo as monotherapy is indicated for the treatment of adult patients with metastatic or locally advanced cutaneous squamous cell carcinoma (mcscc or lacscc) who are not candidates for curative surgery or curative radiation. basal cell carcinomalibtayo as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic basal cell carcinoma (labcc or mbcc) who have progressed on or are intolerant to a hedgehog pathway inhibitor (hhi). non-small cell lung cancerlibtayo as monotherapy is indicated for the first-line treatment of adult patients with non-small cell lung cancer (nsclc) expressing pd-l1 (in ≥ 50% tumour cells), with no egfr, alk or ros1 aberrations, who have:locally advanced nsclc who are not candidates for definitive chemoradiation, ormetastatic nsclc. libtayo in combination with platinum‐based chemotherapy is indicated for the first‐line treatment of adult patients with nsclc expressing pd-l1 (in ≥ 1% of tumour cells), with no egfr, alk or ros1 aberrations, who have:locally advanced nsclc who are not candidates for definitive chemoradiation, ormetastatic nsclc. cervical cancerlibtayo as monotherapy is indicated for the treatment of adult patients with recurrent or metastatic cervical cancer and disease progression on or after platinum-based chemotherapy.